PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vaxcyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$63.68+0.06 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $9.20B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
167M of 149M shares
Institutional holders
331
50 new, 50 sold out
Net institutional buying
21M
In Q2 2026
Insider trades, 12 months
0 buys · 50 sales
Net sold $9.09M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9,825,638 | 7.60% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 7,252,053 | 5.03% | 13G (passive) | Mar 31, 2026 |
| Abigail P. Johnson | 20,798,907 | 14.40% | 13G (passive) amendment | Jun 30, 2026 |
| JANUS HENDERSON GROUP Ltd. | 18,040,375 | 12.10% | 13G (passive) amendment | Jul 31, 2026 |
| Janus Henderson Group PLC | 16,575,875 | 11.50% | 13G (passive) amendment | Mar 31, 2026 |
| FMR LLC | 16,451,061 | 11.40% | 13G (passive) amendment | Mar 31, 2026 |
| RA Capital Management, L.P. | 12,974,599 | 8.90% | 13G (passive) amendment | Mar 31, 2026 |
| Peter Kolchinsky | 12,964,491 | 9.90% | 13G (passive) amendment | Mar 31, 2025 |
| T. Rowe Price Investment Management, Inc. | 11,296,333 | 8.60% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PCVX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 20,852,907 | 14.01% | $1.21B | +4,360,046 | 0.05% |
| Jupiter Topco LLC | 17,965,847 | 12.07% | $1.04B | New | 0.43% |
| T. Rowe Price Investment Management, Inc. | 12,207,450 | 8.20% | $709.62K | +81,433 | 0.47% |
| BlackRock, Inc. | 12,068,129 | 8.11% | $701.52M | +1,096,313 | 0.01% |
| Ra Capital Management, L.P. | 11,474,599 | 7.71% | $667.02M | – | 5.80% |
| Wellington Management Group Llp | 7,001,565 | 4.71% | $407.00M | +1,386,968 | 0.07% |
| Vanguard Portfolio Management LLC | 6,593,551 | 4.43% | $383.28M | +314,006 | 0.02% |
| Vanguard Capital Management LLC | 6,348,679 | 4.27% | $369.05M | +81,978 | 0.01% |
| State Street Corp | 5,351,698 | 3.60% | $311.09M | +911,179 | 0.01% |
| Deep Track Capital, LP | 4,300,000 | 2.89% | $249.96M | – | 3.64% |
| Geode Capital Management, LLC | 3,459,363 | 2.32% | $201.13M | +258,080 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 2,988,999 | 2.01% | $173.75K | +2,012,570 | 0.02% |
| Kynam Capital Management, LP | 2,922,335 | 1.96% | $169.88M | – | 9.39% |
| Westfield Capital Management Co LP | 2,472,428 | 1.66% | $143.72M | −1,173,710 | 0.47% |
| Caligan Partners LP | 2,188,636 | 1.47% | $127.23M | +127,917 | 5.99% |
| Paradigm Biocapital Advisors LP | 2,127,852 | 1.43% | $123.69M | −2,665,168 | 2.32% |
| Bellevue Group AG | 1,971,935 | 1.33% | $114.63M | +781,238 | 2.41% |
| D. E. Shaw & Co., Inc. | 1,901,872 | 1.28% | $110.56M | −963,446 | 0.05% |
| Maverick Capital Ltd | 1,613,242 | 1.08% | $93.78M | +235,504 | 0.83% |
| Charles Schwab Investment Management Inc | 1,464,812 | 0.98% | $85.15M | +60,864 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 331 | 167M | 100.0% | 50 / 132 | 101 / 50 | 38M | 17M |
| Q1 2026 | 336 | 163M | 100.0% | 71 / 128 | 82 / 25 | 36M | 15M |
| Q4 2025 | 295 | 154M | 100.0% | 60 / 95 | 107 / 45 | 27M | 15M |
| Q3 2025 | 286 | 143M | 96.0% | 40 / 100 | 104 / 43 | 13M | 19M |
| Q2 2025 | 294 | 148M | 99.6% | 57 / 132 | 76 / 75 | 26M | 24M |
| Q1 2025 | 315 | 146M | 98.2% | 59 / 128 | 98 / 63 | 17M | 11M |
| Q4 2024 | 323 | 141M | 94.6% | 62 / 139 | 90 / 62 | 18M | 15M |
| Q3 2024 | 329 | 138M | 92.7% | 86 / 129 | 88 / 20 | 30M | 6M |
| Q2 2024 | 265 | 124M | 83.4% | 38 / 116 | 79 / 23 | 9M | 6M |
| Q1 2024 | 251 | 122M | 81.7% | 48 / 103 | 76 / 18 | 23M | 5M |
| Q4 2023 | 223 | 104M | 70.2% | 37 / 87 | 68 / 16 | 9M | 6M |
| Q3 2023 | 202 | 101M | 68.1% | 24 / 86 | 58 / 16 | 7M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PCVX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,587,918 | 3.08% | $266.70M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 4,007,229 | 2.69% | $232.94M | 0.33% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,392,214 | 2.28% | $197.19M | 0.24% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,312,950 | 2.23% | $192.58M | 0.10% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 3,034,105 | 2.04% | $155.95M | 0.06% | May 31, 2026 |
| Janus Henderson Forty Fund | 2,676,774 | 1.80% | $155.60M | 0.65% | Jun 30, 2026 |
| Vanguard Health Care Fund | 2,340,735 | 1.57% | $126.59M | 0.33% | Jul 31, 2026 |
| Janus Henderson Enterprise Fund | 2,269,870 | 1.53% | $131.95M | 0.59% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,192,112 | 1.47% | $127.43M | 1.19% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,911,818 | 1.28% | $111.13M | 0.24% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,507,794 | 1.01% | $87.65M | 0.09% | Jun 30, 2026 |
| Fidelity Advisor Growth Opportunities Fund | 1,477,243 | 0.99% | $75.93M | 0.22% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 1,440,296 | 0.97% | $77.89M | 0.23% | Jul 31, 2026 |
| Vanguard Explorer Fund | 1,318,149 | 0.89% | $71.29M | 0.32% | Jul 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1,302,720 | 0.88% | $75.73M | 0.33% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Grant Pickering | CHIEF EXECUTIVE OFFICER, Director | 563,117 | 0.38% | Sep 9, 2026 |
| Luis Jodar | Chief Medical Officer | 52,632 | 0.04% | Sep 9, 2026 |
| Harpreet S. Dhaliwal | Chief Technical Ops Officer | 68,085 | 0.05% | Sep 9, 2026 |
| Andrew Guggenhime | PRESIDENT AND CFO | 157,166 | 0.11% | Sep 9, 2026 |
| Jim Wassil | EVP, Chief Scientific Ofc, COO | 145,435 | 0.10% | Sep 9, 2026 |
| Elvia Cowan | SVP, Finance & CAO | 27,860 | 0.02% | Sep 9, 2026 |
| Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | 41,732 | 0.03% | Mar 7, 2025 |
| John Markels | Director | 0 | – | Jul 16, 2026 |
| Moncef Slaoui | Director | 0 | – | Jun 23, 2026 |
| Jacks Lee | Director | 6,856 | 0.00% | Jun 16, 2026 |
| Anne S. Drapeau | Director | 12,481 | 0.01% | Jun 16, 2026 |
| Olivier Brandicourt | Director | 4,699 | 0.00% | Jun 16, 2026 |
| Heath Lukatch | Director | 19,481 | 0.01% | Jun 16, 2026 |
| Halley E. Gilbert | Director | 12,481 | 0.01% | Jun 16, 2026 |
| Carlos V. Paya | Director | 12,481 | 0.01% | Jun 16, 2026 |
| John Furey | Director | 5,306 | 0.00% | Jun 16, 2026 |
| Teri Loxam | Director | 12,481 | 0.01% | Jun 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jim Wassil EVP, Chief Scientific Ofc, COO | Sep 9, 2026 | Sale(10b5-1 plan) | −1,334 | $59.52 | $79.40K | 145,435 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Sep 8, 2026 | Tax withholding | −17,056 | $60.36 | $1.03M | 429,902 |
| Andrew Guggenhime PRESIDENT AND CFO | Sep 8, 2026 | Tax withholding | −7,155 | $60.36 | $431.88K | 95,316 |
| Harpreet S. Dhaliwal Chief Technical Ops Officer | Sep 8, 2026 | Tax withholding | −7,651 | $60.36 | $461.81K | 68,085 |
| Elvia Cowan SVP, Finance & CAO | Sep 8, 2026 | Tax withholding | −1,327 | $60.36 | $80.10K | 27,860 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Sep 8, 2026 | Tax withholding | −5,459 | $60.36 | $329.51K | 146,769 |
| Luis Jodar Chief Medical Officer | Sep 4, 2026 | Award | +52,632 | – | – | 52,632 |
| Jim Wassil EVP, Chief Scientific Ofc, COO | Sep 4, 2026 | Sale(10b5-1 plan) | −1,381 | $61.16 | $84.46K | 152,228 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 2, 2026 | Tax withholding | −1,432 | $61.58 | $88.18K | 153,609 |
| Andrew Guggenhime PRESIDENT AND CFO | Sep 2, 2026 | Tax withholding | −1,432 | $61.58 | $88.18K | 102,471 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Sep 2, 2026 | Tax withholding | −3,427 | $61.58 | $211.03K | 446,958 |
| Elvia Cowan SVP, Finance & CAO | Sep 2, 2026 | Tax withholding | −326 | $61.58 | $20.08K | 29,187 |
| Harpreet S. Dhaliwal Chief Technical Ops Officer | Sep 2, 2026 | Tax withholding | −659 | $61.58 | $40.58K | 75,736 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −924 | $60.96 | $56.33K | 155,344 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −713 | $61.48 | $43.84K | 156,268 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −1,537 | $60.89 | $93.59K | 156,981 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 1, 2026 | Option exercise | +2,250 | $5.35 | $12.04K | 158,518 |
| Jim Wassil CHIEF OPERATING OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −303 | $61.42 | $18.61K | 155,041 |
| Jim Wassil CHIEF OPERATING OFFICER | Aug 31, 2026 | Tax withholding | −1,273 | $60.74 | $77.32K | 156,268 |
| Andrew Guggenhime PRESIDENT AND CFO | Aug 31, 2026 | Tax withholding | −1,273 | $60.74 | $77.32K | 103,903 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Aug 31, 2026 | Tax withholding | −2,862 | $60.74 | $173.84K | 450,385 |
| Elvia Cowan SVP, Finance & CAO | Aug 31, 2026 | Tax withholding | −243 | $60.74 | $14.76K | 29,513 |
| Harpreet S. Dhaliwal Chief Technical Ops Officer | Aug 31, 2026 | Tax withholding | −361 | $60.74 | $21.93K | 76,395 |
| Harpreet S. Dhaliwal Chief Technical Ops Officer | Aug 5, 2026 | Option exercise | +17,000 | $24.79 | $421.43K | 93,756 |
| Harpreet S. Dhaliwal Chief Technical Ops Officer | Aug 5, 2026 | Sale(10b5-1 plan) | −17,000 | $55.00 | $935.00K | 76,756 |
| Andrew Guggenhime PRESIDENT AND CFO | Aug 3, 2026 | Sale(10b5-1 plan) | −3,044 | $54.18 | $164.92K | 105,176 |
| Andrew Guggenhime PRESIDENT AND CFO | Aug 3, 2026 | Option exercise | +10,000 | $5.35 | $53.50K | 115,176 |
| Andrew Guggenhime PRESIDENT AND CFO | Aug 3, 2026 | Sale(10b5-1 plan) | −6,956 | $53.76 | $373.95K | 108,220 |
| Jim Wassil CHIEF OPERATING OFFICER | Aug 3, 2026 | Sale(10b5-1 plan) | −1,389 | $54.09 | $75.13K | 157,541 |
| Jim Wassil CHIEF OPERATING OFFICER | Aug 3, 2026 | Sale(10b5-1 plan) | −861 | $53.50 | $46.06K | 158,930 |
| Jim Wassil CHIEF OPERATING OFFICER | Aug 3, 2026 | Option exercise | +2,250 | $5.35 | $12.04K | 159,791 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −378 | $55.91 | $21.13K | 133,215 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −11,783 | $55.52 | $654.19K | 457,662 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −4,415 | $55.93 | $246.93K | 453,247 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −756 | $55.52 | $41.97K | 133,459 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −244 | $55.96 | $13.65K | 133,215 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Sale(10b5-1 plan) | −622 | $55.54 | $34.55K | 133,593 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jul 27, 2026 | Option exercise | +16,198 | $2.03 | $32.88K | 469,445 |
| Andrew Guggenhime PRESIDENT AND CFO | Jul 6, 2026 | Sale(10b5-1 plan) | −7,913 | $57.16 | $452.31K | 106,482 |
| Andrew Guggenhime PRESIDENT AND CFO | Jul 6, 2026 | Sale(10b5-1 plan) | −2,087 | $57.76 | $120.55K | 104,395 |
| Andrew Guggenhime PRESIDENT AND CFO | Jul 6, 2026 | Option exercise | +10,000 | $5.35 | $53.50K | 114,395 |
| Jim Wassil CHIEF OPERATING OFFICER | Jul 1, 2026 | Sale(10b5-1 plan) | −1,788 | $56.03 | $100.18K | 157,222 |
| Jim Wassil CHIEF OPERATING OFFICER | Jul 1, 2026 | Sale(10b5-1 plan) | −456 | $57.47 | $26.21K | 156,766 |
| Jim Wassil CHIEF OPERATING OFFICER | Jul 1, 2026 | Sale(10b5-1 plan) | −6 | $57.82 | $347 | 156,760 |
| Jim Wassil CHIEF OPERATING OFFICER | Jul 1, 2026 | Option exercise | +516 | $5.35 | $2.76K | 159,010 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −332 | $55.99 | $18.59K | 134,215 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −356 | $55.23 | $19.66K | 134,547 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −312 | $54.35 | $16.96K | 134,903 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −6,417 | $56.12 | $360.12K | 452,466 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −9,137 | $55.27 | $505.00K | 458,883 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −6,683 | $54.28 | $362.75K | 468,020 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −191 | $56.27 | $10.75K | 134,215 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −602 | $55.30 | $33.29K | 134,406 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −207 | $54.22 | $11.22K | 135,008 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 18, 2026 | Sale(10b5-1 plan) | −1,000 | $52.50 | $52.50K | 135,215 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 18, 2026 | Sale(10b5-1 plan) | −1,000 | $52.50 | $52.50K | 135,215 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 18, 2026 | Sale(10b5-1 plan) | −225 | $52.51 | $11.81K | 496,939 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 18, 2026 | Sale(10b5-1 plan) | −22,236 | $52.50 | $1.17M | 474,703 |
| Grant Pickering CHIEF EXECUTIVE OFFICER, Director | Jun 18, 2026 | Option exercise | +225 | $1.79 | $403 | 497,164 |
| Andrew Guggenhime PRESIDENT AND CFO | Jun 18, 2026 | Option exercise | +10,000 | $5.35 | $53.50K | 114,395 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Elvia Cowan Officer | Oct 5, 2026 | 19,000 | $1.65M | Oct 5, 2026 | Exercise of Stock Options |
| Jim Wassil Officer | Oct 5, 2026 | 18,000 | $1.56M | Oct 5, 2026 | Exercise of stock option |
| Jim Wassil Officer | Oct 1, 2026 | 2,250 | $127.64K | Oct 1, 2026 | Exercise of stock option |
| Jim Wassil Officer | Sep 9, 2026 | 1,334 | $80.03K | Sep 9, 2026 | RSU Vest |
| Jim Wassil Officer | Sep 4, 2026 | 1,381 | $82.49K | Sep 4, 2026 | RSU Vest |
| Jim Wassil Officer | Sep 1, 2026 | 3,477 | $209.63K | Sep 1, 2026 | RSU Vest |
| Harpreet S. Dhaliwal Officer | Aug 5, 2026 | 17,000 | $935.00K | Aug 5, 2026 | Exercise of Stock Options |
| Jim Wassil Officer | Aug 3, 2026 | 2,250 | $121.48K | Aug 3, 2026 | Exercise of stock options |
| Andrew Guggenhime Officer | Aug 3, 2026 | 10,000 | $539.90K | Aug 3, 2026 | Exercise of Stock Options |
| Grant Pickering Officer, Director | Jul 27, 2026 | 18,198 | $996.70K | Jul 27, 2026 | Exercise of Stock Options |
| Andrew Guggenhime Officer | Jul 6, 2026 | 10,000 | $577.60K | Jul 6, 2026 | Exercise of Stock Options |
| Jim Wassil Officer | Jul 1, 2026 | 2,250 | $130.79K | Jul 1, 2026 | RSU Vest |
| Grant Pickering Officer, Director | Jun 26, 2026 | 24,237 | $1.30M | Jun 26, 2026 | RSU Vest |
| Grant Pickering Officer | Jun 18, 2026 | 24,461 | $1.28M | Jun 18, 2026 | Exercise of stock options |
| Andrew Guggenhime Officer | Jun 18, 2026 | 10,000 | $530.00K | Jun 18, 2026 | Exercise of Stock Options |